Telomir Pharmaceuticals Inc (TELO) FinancialsTELOTelomir Pharmaceuticals Inc

Evaluating the bottom line, Telomir Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1885.50%, provide a clear picture of how effectively TELO converts its operational activities into shareholder value.

In the context of the broader market, TELO competes directly with industry leaders such as MNOV and NMRA. With a market capitalization of $50.16M, it holds a significant position in the sector. When comparing efficiency, TELO's gross margin of N/A stands against MNOV's 69.31% and NMRA's N/A. Such benchmarking helps identify whether Telomir Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Telomir Pharmaceuticals has reported consistent losses, with a net income of -47835431 in Q2 2026 and an EPS of -0.79 in the last earnings report. The company's forward P/E is currently at 0, indicating no expected earnings growth in the near term.